In the United States, BiDil, a medicine for heart conditions produced by the NitroMed pharmaceutical company, was finally authorized by the Food and Drug Administration (FDA) after several decades waiting as its effectiveness had not been tested in the population. In effect, NitroMed has just renovated the patent of its formula, now aiming mainly at the black population, after confirming a 43% decrease in mortality and a 39% decrease in hospitalizations for heart problems among black patients who used it. The fact that there is no scientific element to prove that black people are more sensitive to the medicine causes a thorny debate like it happens every time that any predisposition is linked to the people’s skin color. Thus, taking into account the long record of racial discrimination of the American society and the health consequences that this case entails, it would be right to ask whether NitroMed is simply trying to exploit a market developed by the food industry among the poorer classes of the population and using the current debate as a publicity campaign.